A KRAS mutation is not a strategy: Why allele, co-mutation, and tumor type matter
Trends in Oncology
Champions Oncology
A KRAS mutation is not a strategy: Why allele, co-mutation, and tumor type matter
The next KRAS battleground: modelling resistance before the clinic
Why Benchmarking is Now Essential in KRAS Drug Development
KRAS Has Entered a New Era. Why Your Preclinical Strategy Must Change Now
Daraxonrasib Is Rewriting the Standard of Care. Here's Why Preclinical Benchmarking Matters Now
Clinically Relevant 3D Tumor Models for HER2-Targeted ADC Development
Evaluating a Novel GCN2 Inhibitor for Acute Myeloid Leukemia (AML) Treatment Using Patient-Derived Models
Data Ecosystem
Not All Tumors Look Alike: Using Surfaceome Diversity to Enrich Responders
Data Ecosystem
Beyond Single Omic Biomarkers: How Proteogenomic ML Reveals Therapy Vulnerabilities
Feature selection in RNA-seq and proteomics with MADVAR in R
Choosing the Right CDX Models: Speed, Scientific Value, and Translational Relevance